GlassScriptPhysician profile
April Page
NPI 1821720004
$1,602.40
in general payments reported to CMS, 2019-2025
18 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $341 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $230.92 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $214.23 | 2025 | |
| Merck Sharp & Dohme LLC | $204.64 | 2024-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $134.91 | 2024-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $116.32 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $97.50 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $77.38 | 2024-2025 | Zoryve |
| Glaxosmithkline, LLC. | $64.38 | 2024-2025 | Trelegy Ellipta |
| Abbvie INC. | $62.76 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.02 | 2024-2025 | Caplyta |
| Grifols USA, LLC | $58.74 | 2025 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $58.66 | 2024-2025 | |
| Exact Sciences Corporation | $53.63 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $44.72 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $41.47 | 2024-2025 | Gemtesa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.43 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $29.42 | 2025 | Trintellix |
| Amgen INC. | $19.27 | 2025 | Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.